Over 90 percent of people with Huntington’s disease develop chorea. Learn about FDA-approved VMAT2 inhibitors, off-label ...

SAN DIEGO, Sept. 30, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) (Nasdaq: NBIX) today announced interim results from the ongoing open-label KINECT ®-HD2 study of INGREZZA ® (valbenazine) ...

Please provide your email address to receive an email when new articles are posted on . The new once-daily tablet strength doses are 30 mg, 36 mg, 42 mg and 48 mg. Symptom improvement in tardive ...

ROCKVILLE, Md., Aug. 15 -- The FDA has approved tetrabenazine (Xenazine), the first agent for chorea in Huntington's disease, the involuntary jerky movements that are a hallmark of the condition. "For ...

Data Reinforce the Clinically Meaningful Impact of INGREZZA in Adults with Huntington's Disease Chorea Findings Presented at the 2025 American Association of Neuroscience Nurses Neuroscience Advanced ...

Huntington's disease is a devastating brain disorder that slowly robs people of movement, memory, and personality. It is caused by a toxic protein that builds in brain cells and ultimately kills them.

Amy Aungst, center right, organizes walks in Cape Henlopen, Delaware, to raise awareness about Huntington’s disease, a rare condition that is estimated to affect about 30,000 or more U.S. adults.

Heidi Pauselli knew there was a high chance she would one day be diagnosed with Huntington’s disease after her grandmother ...